Article Sidebar

PDF (Tiếng Việt)
Published: 2024-07-31
Abstract Views: 141
Views PDF (Tiếng Việt): 71
DOI: https://doi.org/10.52852/tcncyh.v179i6.2488
Issue
Vol. 179 No. 6 (2024)
Section
Các bài báo
How to Cite
Bách, T. T., Nhật, N. M., Xuân, V. V., Phương, P. C., & Hiếu, N. V. (2024). 17. Systemic immune-inflammation indexes and primary outcome after radical concurent chemoradiotherapy in upper third esophageal squamous cell carcinoma. Journal of Medical Research, 179(6), 155-165. https://doi.org/10.52852/tcncyh.v179i6.2488

17. Systemic immune-inflammation indexes and primary outcome after radical concurent chemoradiotherapy in upper third esophageal squamous cell carcinoma

Tran Trung Bach, Nguyen Minh Nhat, Vo Van Xuan, Pham Cam Phuong, Nguyen Van Hieu

Main Article Content

Abstract

A descriptive study was performed in 40 male patients diagnosed with upper third esophageal squamous cell carcinoma at the General Radiotherapy Department of Vietnam National Cancer Hospital from January 2022 to September 2023 to describe the association between clinical characteristics, systemic immune-inflammation indexes and primary outcome after radical concurent chemoradiotherapy in upper third esophageal squamous cell carcinoma. The average age is 60.9 years. Tumor length, PNI (prognostic nutritional index) and radiotherapy duration are factors related to post-treatment response (p < 0.05). In univariate logistic regression analysis, tumor length, PNI and radiotherapy duration are independent predictive factors for treatment response (p < 0.05). In multivariable logistic regression analysis, SII (systemic immune-inflammation index) is an independent factor predicting response to treatment (p < 0.05).

Article Details

Keywords

Esophageal squamous cell carcinoma, upper third, concurent chemoradiotherapy, systemic immune-inflammation indexes

References

1. Hoeben A, Polak J, Voorde LVD, Hoebers F, Grabsch HI, Vos-Geelen J de. Cervical esophageal cancer: a gap in cancer knowledge. Annals of Oncology. 2016; 27(9): 1664-1674. doi:10.1093/annonc/mdw183.
2. De Virgilio A, Costantino A, Festa BM, et al. Oncological outcomes of cervical esophageal cancer treated primarily with surgery: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2023; 280(1): 373-390. doi:10.1007/s00405-022-07589-z.
3. Patel DC, Yang CFJ, Liou DZ, Berry MF. Treatment and Outcomes of Proximal Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2023; 30(2): 818-827. doi:10.1245/s10434-022-12683-x.
4. Buckstein M, Liu J. Cervical Esophageal Cancers: Challenges and Opportunities. Curr Oncol Rep. 2019; 21(5): 46. doi:10.1007/s11912-019-0801-7.
5. Valmasoni M, Pierobon ES, Zanchettin G, et al. Cervical Esophageal Cancer Treatment Strategies: A Cohort Study Appraising the Debated Role of Surgery. Ann Surg Oncol. 2018; 25(9): 2747-2755. doi:10.1245/s10434-018-6648-6.
6. de Vos-Geelen J, Geurts SME, Nieuwenhuijzen GAP, et al. Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer. European Journal of Surgical Oncology. 2021; 47(8): 2016-2022. doi:10.1016/j.ejso.2021.02.001.
7. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010; 140(6): 883-899. doi:10.1016/j.cell.2010.01.025.
8. Zeng X, Ye L, Luo M, Zeng D, Chen Y. Prognostic value of pretreatment systemic immune-inflammation index in Chinese esophageal squamous cell carcinoma patients receiving radical radiotherapy: A meta-analysis. Medicine (Baltimore). 2023; 102(25): e34117. doi:10.1097/MD.0000000000034117.
9. Zhang H, Shang X, Ren P, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. Journal of Cellular Physiology. 2018; 234(2): 1794-1802. doi:10.1002/jcp.27052.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009; 45(2): 228-247. doi:10.1016/j.ejca.2008.10.026.
11. Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018; 19(7): 965-974. doi:10.1016/S1470-2045(18)30201-8.
12. Xu H, Wu S, Luo H, et al. Prognostic value of tumor length and diameter for esophageal squamous cell cancer patients treated with definitive (chemo)radiotherapy: Potential indicators for nonsurgical T staging. Cancer Med. 2019; 8(14): 6326-6334. doi:10.1002/cam4.2532.
13. Hulshof MCCM, Geijsen D, Rozema T, et al. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. JCO. 2020; 38(4_suppl): 281-281. doi:10.1200/JCO.2020.38.4_suppl.281.
14. Li X, Zhang S, Lu J, Li C, Li N. The prognostic value of systemic immune-inflammation index in surgical esophageal cancer patients: An updated meta-analysis. Front Surg. 2022; 9:922595. doi:10.3389/fsurg.2022.922595.
15. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30(7): 1073-1081. doi:10.1093/carcin/bgp127.